The Oncotype DX Genomic Prostate Score provides a comprehensive risk profile for personalized information to guide treatment decisions.
Oncotype DX GPS is proven to be an independent predictor of:
- Prospectively validated as an independent predictor of both prostate cancer death and metastasis at 10 years1*
- Predicts future tumor behavior and helps patients understand long-term prognosis to ease patient concerns and offer reassurance1
- Prospectively validated as an independent predictor of adverse pathology2,3†
- The most important and actionable endpoint when individualizing patient management4,5
- Identifies patients with less aggressive disease who are likely candidates for Active Surveillance